NZ812114A - Solid forms of pyrazolo[3,4-d]pyrimidine compounds - Google Patents

Solid forms of pyrazolo[3,4-d]pyrimidine compounds

Info

Publication number
NZ812114A
NZ812114A NZ812114A NZ81211422A NZ812114A NZ 812114 A NZ812114 A NZ 812114A NZ 812114 A NZ812114 A NZ 812114A NZ 81211422 A NZ81211422 A NZ 81211422A NZ 812114 A NZ812114 A NZ 812114A
Authority
NZ
New Zealand
Prior art keywords
pyrazolo
solid forms
pyrimidine compounds
solid form
ray powder
Prior art date
Application number
NZ812114A
Other versions
NZ812114B2 (en
Inventor
Caroline Yvette Proulx-Lafrance
Erika Volckova
Jr John C Amedio
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NZ812114A publication Critical patent/NZ812114A/en
Publication of NZ812114B2 publication Critical patent/NZ812114B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present disclosure provides solid forms of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, and methods of preparing and using the same.

Claims (5)

1. A solid form of Compound X: 5 wherein the solid form is selected from: Form A: characterized by having X-ray powder diffraction peaks at approximately 18.9, 20.4, and 23.1 °2? using Cu K? radiation, and Form B: characterized by having X-ray powder diffraction peaks at approximately 8.0, 15.0, and 19.3 °2? using Cu K? radiation.
2. The solid form of claim 1, wherein the solid form is Form A.
3. The solid form of claim 2, wherein the Form A is characterized by having X-ray powder ction peaks at approximately 9.6± 0.2, 17.2± 0.2, 18.9± 0.2, 20.4± 0.2, and 15 23.1± 0.2 °2? using Cu K? radiation.
4. The solid form of claim 2, wherein the Form A is characterized by having X-ray powder diffraction peaks at approximately 9.6± 0.2, 17.2± 0.2, 18.9± 0.2, 20.4± 0.2, 20.7± 0.2, 21.9± 0.2, 23.1± 0.2, and 24.5± 0.2 °2? using Cu K? radiation.
5. The solid form of claim 2, wherein the X-ray powder diffraction pattern is substantially the same to that set forth in
NZ812114A 2022-12-16 Solid forms of pyrazolo[3,4-d]pyrimidine compounds NZ812114B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163290136P 2021-12-16 2021-12-16
PCT/US2022/081795 WO2023114995A1 (en) 2021-12-16 2022-12-16 Solid forms of pyrazolo[3,4-d]pyrimidine compounds

Publications (2)

Publication Number Publication Date
NZ812114A true NZ812114A (en) 2025-08-29
NZ812114B2 NZ812114B2 (en) 2025-12-02

Family

ID=

Also Published As

Publication number Publication date
CA3242577A1 (en) 2023-06-22
US12012412B2 (en) 2024-06-18
US20240300961A1 (en) 2024-09-12
TW202333676A (en) 2023-09-01
JP2024546844A (en) 2024-12-26
IL313314A (en) 2024-08-01
CN118401525A (en) 2024-07-26
KR20240119299A (en) 2024-08-06
AU2025275149A1 (en) 2026-01-08
WO2023114995A1 (en) 2023-06-22
EP4448529A1 (en) 2024-10-23
AU2022416644B2 (en) 2025-09-11
AU2022416644A1 (en) 2024-07-04
MX2024007517A (en) 2024-08-19
US20230192707A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
WO2024229444A3 (en) Pyrido[4,3-d]pyrimidine derivatives as mutant kras g12c inhibitors for the treatment of cancer
EP4232444A1 (en) Heterocyclic spiro compounds and methods of use
NZ590922A (en) Piperidine derivatives as jak3 inhibitors
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
NZ758243A (en) Indole ahr inhibitors and uses thereof
MY146474A (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
CA2413802A1 (en) Substituted-triazolopyrimidines as anticancer agents
CA3242577A1 (en) Solid forms of pyrazolo[3,4-d]pyrimidine compounds
CA2388140A1 (en) Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
PH12013501627A1 (en) Compositions, suitable for oral administration, comprising a triazolo [4, 5-d]pyrimidin derivative
MX2020009586A (en) SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-a] PYRIMIDINE AND IMIDAZO [1, 2-b] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS.
FI3798222T3 (en) Crystalline form of lorlatinib free base
SG10201900514RA (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
CR20240297A (en) Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
NZ812114B2 (en) Solid forms of pyrazolo[3,4-d]pyrimidine compounds
ZA202401459B (en) Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one
WO2022023447A3 (en) Fused bicyclic raf inhibitors and methods for use thereof
GB2552269A (en) Substituted pyrrolo(2,3-D)pyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors
FI4244208T3 (en) A magl inhibitor
CA2477516A1 (en) Pharmaceutical formulation comprising melatonin
KR960700246A (en) 5-alkoxytriazolo (1,5-C) pyrimidine-2 (3H) -thione compound, and 2,2-dithiobistriazolo- (1,5-C) -pyrimidine) and 2-chlorosulfonyl Its use in the production of -5-alkoxytriazolo (1,5-C) pyrimidine compounds (5-Alkoxy [1,2,4] triazolo [1,5-c] pyrimidine-2 (3H) -thione compounds and their use in the preparation of 2,2'-dithiobis (5-alkoxy [1,2,4] triazolo [1,5-c] -pyrimidine) and 2-chlorosufonyl-5-alkoxy [1,2,4 ] triazolo [1,5-c] pyrimidine compounds)
WO2022194909A3 (en) Process for preparing risdiplam
DE60100855D1 (en) 1,8-NAPHTHALIMID IMIDAZO [4,5,1-DE] ACRIDONE WITH ANTITUARY EFFECT
WO2025043225A3 (en) Dioxopiperidine-indolone-methylene-carbamate compounds as degraders of cyclin-dependent kinase 2
GB9828340D0 (en) Organic compounds

Legal Events

Date Code Title Description
PSEA Patent sealed